Optimizing Transition of Care in Multiple Myeloma: Bridging the Gap Between Academic and Community Settings : Episode 6
Monitoring Adverse Events Following CAR T-Cell Therapy
A panel of oncologists in academic and community settings discuss patient monitoring practices following CAR T-cell infusions, with a focus on neurotoxicities.
EP: 1.Identifying Potential Candidates for CAR T-Cell Therapy
EP: 2.Treating Patients Referred to Academic Centers for CAR T
EP: 3.CAR T-Cell Therapy: Leukapheresis Practices
EP: 4.Triaging and Prioritizing Patients with Multiple Myeloma
EP: 5.Transitioning Patients Back to Community Practices Following CAR T
Now Viewing
EP: 6.Monitoring Adverse Events Following CAR T-Cell Therapy
EP: 7.Educating Patients on Complications Associated with CAR T-Cell Therapy
EP: 8.Improving Access for Patients Receiving CAR T-Cell Therapy
EP: 9.Collaborative Education for CAR T-Cell Therapy
EP: 10.Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings
- Dr. Usmani: What is your protocol for monitoring and grading of neurotoxicity, cytokine release syndrome (CRS), and other acute toxicities immediately following CAR-T cell infusion?
- Are there any subgroups of patients you have found to be at particularly high risk for delayed neurotoxicity requiring extended monitoring?
- What are your institutional guidelines around administering steroids, anti-seizure medications, or other treatments for severe neurotoxicity?
Recent Videos
Related Content
